CLINICAL LABORATORY INDICATORS OF PREGNANT WITH ANTIPHOSPHOLIPID SYNDROME IN COMPLEX THERAPY WITH USING INTRAVENOUS IMMUNOGLOBULIN
https://doi.org/10.17749/2070-4968.2015.9.3.011-016
Abstract
About the Author
V. I. LinnikovRussian Federation
MD, professor, Senior scientific consultant, Medical Genetic Center «GerMedTech»
References
1. Makatsariya A.D., Bitsadze V.O., Khizroeva D.Kh., Makatsariya N.A., Yashenina E.V. Prakticheskaya meditsina. 2012; 5: 9-20.
2. Makatsariya A.D., Bitsadze V.O. Thrombophilia and antithrombotic therapy in obstetric practice [Trombofiliya i protivotromboticheskaya terapiya v akusherskoi praktike (in Russian)]. Moscow. 2003; 904 s.
3. Makatsariya A.D., Bitsadze V.O., Baimuratova S.M., Dolgushina N.V., Yudaeva L.S., Khizroeva D.Kh., Akin'shina S.V. Antiphospholipid syndrome – the immune thrombophilia in obstetrics and gynecology [Antifosfolipidnyi sindrom – immunnaya trombofiliya v akusherstve i ginekologii (in Russian)]. Moscow. 2013; 485 s.
4. Sel'kov A.V., Selyutin A.V. Laboratornaya diagnostika. 2008; 4: 19-21.
5. Sidel'nikova V.M. The usual pregnancy loss [Privychnaya poterya beremennosti (in Russian)]. Moscow. 2005; 304-307.
6. Yarilin A.A., Donetskova F.D. Regulyatornye T-kletki, zavisimye ot faktora FOXp3, i perspektivy ikh izucheniya pri beremennosti. Rus J. Immunol. 2005; 9: 149-152.
7. Branch D.W., Peaceman A.M., Silver R.K. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000; 182 (1): 122-127.
8. Carp H., Sapir T., Shoenfeld Y. Inravenous immunoglobulin and recurrent pregnancy loss. Clin. Rev. Allegy Immunol. 2005; 29 (3): 327-332.
9. Coulam C.D., Roussev R.G. Correlation of NK cell activation and inhibition markers with NK cytoxicity among women experiencing immunologic implantation failure after in vitro ferilization and embryotransfer. J. Ass. Reprod. Genet. 2003; 20: 58-62.
10. Guerin L.R. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Human Reproduction Update. 2009; 15 (5): 535-571.
11. Chen M.L., Pittet M.J., Gorelik Regulatry I. T-cells suppress tumor-specific CD8 T-cell cytotoxity through TGF-b signals in vivo. Proc. Nath. Acaci. Sci USA. 2005; 102: 409-424.
12. Christiansen O.D. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarnage evidence for a therapeutic effect in women with secondry recurrent miscamage. Hum. Reprod. 2002; 17: 809-816.
13. Shoenfeld Y., Kutz U. IVIG therapy in autoimmunity and related disorders our experience with a large cohort of patients. Autoimmunity. 2005; 38 (2): 123-137.
14. Stricker R.B., Stenleitner A., Winger E.E. Intravenous immunoglobulin therapy for immunologic abortion. Clin. Appl. Rev. 2002; 43: 187-199.
15. Stephenson M. Inravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebocontrolled trial. M. Stephenson. Hum. Reprod. 2010; 25 (9): 2203-1209.
16. Tzronkowski P., Szit E., Mysliwska E. CD4+ CD25+ T-regulatory cells ingibit human cytotoxic activity of CTL and NK-cells in humans – impact of immunosensence. Clin. Immunol. 2006; 119: 307-312.
17. Triolo G. IVIG in pregnancy. Lupus. 2004; 13 (9): 731-736.
Review
For citations:
Linnikov V.I. CLINICAL LABORATORY INDICATORS OF PREGNANT WITH ANTIPHOSPHOLIPID SYNDROME IN COMPLEX THERAPY WITH USING INTRAVENOUS IMMUNOGLOBULIN. Obstetrics, Gynecology and Reproduction. 2015;9(3):11-16. (In Russ.) https://doi.org/10.17749/2070-4968.2015.9.3.011-016

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.